MARKET

IONS

IONS

Isis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

61.73
+0.16
+0.26%
Closed 18:05 02/19 EST
OPEN
61.72
PREV CLOSE
61.57
HIGH
61.85
LOW
60.88
VOLUME
427.90K
TURNOVER
--
52 WEEK HIGH
86.58
52 WEEK LOW
53.34
MARKET CAP
8.68B
P/E (TTM)
89.97
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IONS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

IONS News

  • Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
  • Zacks.19h ago
  • UBS Commercial Mortgage Trust 2017-C3 -- Moody's affirms seven CMBS classes of UBSCM 2017-C3
  • Moody's.21h ago
  • Ionis Pharmaceuticals to hold 2019 financial results webcast
  • PR Newswire.1d ago
  • Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
  • GlobeNewswire.02/13 12:00

More

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.22%

Hot Stocks

Name
Price
%Change

About IONS

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
More

Webull offers Ionis Pharmaceuticals Inc (IONS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.